Skip to main content
Mijn bibliotheek
Shop
Nieuws
Boeken
Tijdschriften
E-learning
Web-tv
Video
Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Quality of Life Research

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Quality of Life Research 11/2016

23-05-2016

Adaptation and validation of the “tolerability and quality of life” (TOOL) questionnaire in Chinese bipolar patients

Auteurs: Lin Xiao, Yulin Gao, Lili Zhang, Peiyun Chen, Xiaojia Sun, Siyuan Tang

Gepubliceerd in: Quality of Life Research | Uitgave 11/2016

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Background

It is well known that the antipsychotic drugs impact the health-related quality of life (HRQoL) of the bipolar patients. The side effects had been assessed only from the doctors’ perspective and neglected the patients’ subjective feeling. The aim of the study is to validate the specific instrument “tolerability and quality of life” (TOOL) into Chinese to describe and grade the impact of antipsychotic drugs on HRQoL from patients’ view.

Methods

A psychometric study was conducted with euthymic bipolar disorder patients (N = 105) under antipsychotic treatment. The psychometric properties of the TOOL, including internal consistency, retest reliability, concurrent validity, content validity, discriminative validity, item analysis, confirmatory factor analysis and feasibility, were analyzed.

Results

The internal consistency and intraclass correlation coefficient (ICC) were adequate (Cronbach’s alpha = 0.80 and ICC = 0.81). A confirmatory factor analysis (CFA) validated the one-factor model. Significant Spearman’s rank correlations between the TOOL and both Bref QoL.BD (Brief version of Quality of Life in Bipolar Disorder) (r = −0.33, P < 0.01) and UKU (Udvalg for Kliniske Undersogelser side effects scale) (r = 0.13, P < 0.05) were found.

Limitations

Small sample size and no specific self-report instrument in Chinese to evaluate the criterion validity.

Conclusions

TOOL appears to be a reliable and valid measure to assess the impact of adverse events of antipsychotic drugs on HRQoL from the patients’ perspective.
vorige artikel Reliability and validity of PROMIS measures administered by telephone interview in a longitudinal localized prostate cancer study
volgende artikel The development and acceptability of symptom management quality improvement reports based on patient-reported data: an overview of methods used in PROSSES
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
Buckley, P. F. (2008). Update on the etiology and treatment of schizophrenia and bipolar disorder. CNS Spectrums, 13(Suppl 1), 3–10.
2.
Edwards, S. J., & Smith, C. J. (2009). Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: A mixed treatment comparison of randomized controlled trials. Clinical Therapeutics, 31, 1345–1359. CrossRefPubMed
3.
Elmslie, J. L., Silverstone, J. J., Mann, J. I., Williams, S. M., & Romans, S. E. (2000). Prevalence of overweight and obesity in bipolar patients. Journal of Clinical Psychiatry, 61(3), 179–184. CrossRefPubMed
4.
Fagiolini, A., Chengappa, K. N., Soreca, I., & Chang, J. (2008). Bipolar disorder and the metabolic syndrome: Causal factors, psychiatric outcomes and economic burden. CNS Drugs, 22(8), 655–669. CrossRefPubMed
5.
Kolotkin, R. L., Corey, L., & Crosby, R. D. (2008). Impact of obesity on HRQoL in schizophrenia and bipolar disorder. Obesity, 16, 749–754. CrossRefPubMed
6.
Berk, M., & Berk, L. (2003). Mood stabilizers and treatment adherence in bipolar disorder: Addressing adverse events. Annals of Clinical Psychiatry, 15(3), 217–224. CrossRefPubMed
7.
Chue, P., & Kovacs, C. S. (2003). Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: Prevalence, monitoring and management. Bipolar Disorders, 5(Suppl 2), 62–79. CrossRefPubMed
8.
Johnson, F. R., Ozdemir, S., Manjunath, R., Hauber, A. B., Burch, S. P., & Thompson, T. R. (2007). Factors that affect adherence to bipolar disorder treatments: A stated-preference approach. Medical Care, 45(6), 545–552. CrossRefPubMed
9.
Sachs, G. S. (2003). Unmet clinical needs in bipolar disorder. Journal of Clinical Psychopharmacology, 23(Suppl 1), S2–S8. PubMed
10.
Lingam, R., & Scott, J. (2002). Treatment non-adherence in affective disorders. Acta Psychiatrica Scand., 105(3), 164–172. CrossRef
11.
Endicott, J., Paulsson, B., Gustafsson, U., Schioler, H., & Hassan, M. (2008). Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep. Journal of Affective Disorders, 111(2–3), 306–319. CrossRefPubMed
12.
Yen, C. F., Cheng, C. P., Huang, C. F., Yen, J. Y., Ko, C. H., & Chen, C. S. (2008). Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission. Bipolar Disorders, 10(5), 617–624. CrossRefPubMed
13.
Awad, A. G., Hogan, T. P., Voruganti, L. N., & Heslegrave, R. J. (1995). Patients’ subjective experiences on antipsychotic medications: Implications for outcome and quality of life. International Clinical Psychopharmacology, 10, 123–132. PubMed
14.
Ritsner, M., Modai, I., Endicott, J., Rivkin, O., Nechamkin, Y., Barak, P., et al. (2000). Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. Journal of Clinical Psychiatry, 61(11), 880–889. CrossRefPubMed
15.
Reine, G., Lancon, C., Di, T. S., Sapin, C., & Auquier, P. (2003). Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatrica Scandinavica, 108(4), 297–303. CrossRefPubMed
16.
Taksh, U. (2006). A critical review of rating scales in the assessment of movement disorders in schizophrenia. Current Drug Targets, 7(9), 1225–1229. CrossRefPubMed
17.
Lingjaerde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica, 334, 1–100. CrossRefPubMed
18.
Thornicroft, G., & Tansella, M. (2005). Growing recognition of the importance of service user involvement in mental health service planning and evaluation. Epidemiologia e Psichiatria Sociale, 14(1), 1–3. CrossRefPubMed
19.
Montejo, A. L. (2008). Prolactin awareness: An essential consideration for physical health in schizophrenia. European Neuropsychopharmacology, 18(Suppl 2), S108–S114. CrossRefPubMed
20.
Montejo, A. L., Correas-Lauffer, J., Mauriño, J., Villa, G., Rebollo, P., Díez, T., & Cordero, L. (2011). Estimation of a multiattribute utility function for the Spanish version of the TOOL questionnaire. Value in Health, 14(4), 564–570. CrossRefPubMed
21.
Lindstrom, E., Jonsson, L., & Berntsson, A. (2009). A patient perspective on side effects of antipsychotic therapy: The TOOL instrument. Value in Health, 12(7), A361. CrossRef
22.
Jonsson, L., Lang, A., & Lindstrom, E. (2009). TOOL: Multi-attribute utility function reflecting patient experience of side effects to antipsychotic therapy. Value in Health, 12(7), A361. CrossRef
23.
Montejo, A. L., Lauffer, J. C., Cuervo, J., Rebollo, P., Cordero, L., Diez, T., & Maurino, J. (2011). Validation of a specific measure to assess health related quality of life in patients with schizophrenia and bipolar disorder: The ‘Tolerability and quality of life’ (TOOL) questionnaire. Annals of General Psychiatry, 10(1), 6. CrossRefPubMedPubMedCentral
24.
Maurino, J., Cordero, L., Montejo, A. L., Correas-Lauffer, J., Cuervo, J., Rebollo, P., et al. (2009). The Spanish version of the TOOL questionnaire: Validation of a specific measure to evaluate health related quality of life in patients with schizophrenia and bipolar disorder. Value in Health, 12(7), A362. CrossRef
25.
Maurino, J., Cordero, L., Montejo, A., Rebollo, P., & Cuervo, J. (2008). The Spanish version of the TOOL questionnaire: A useful measure for evaluating the HRQoL and utilities from schizophrenic and bipolar patients. Value in Health, 11(6), A593. CrossRef
26.
Gandek, B., & Ware, J. E. (1998). Methods for validating and norming translations of health status questionnaires: The IQOLA project approach. Journal of Clinical Epidemiology, 51(11), 953–959. CrossRefPubMed
27.
28.
Bech. (1979). The Bech-Rafaelsen Mania Scale and Hamilton Depression Scale. Acta Psychiatrica Scandinavica, 59, 420–429. CrossRefPubMed
29.
Zhang, Z. J. (2001). Hamilton Depression Scale. Chinese Journal of Behavioral Medical Science, 10, 134–135.
30.
Cui, S. (1985). Bech-Rafaelsen Mania Rating Scale for the assessment of manic patients. Chinese Journal of Nervous and Mental Diseases, 18, 267–269.
31.
Michalak, E. E., Murray, G., & CREST.BD. (2010). Development of the QoL.BD: A disorder specific scale to assess quality of life in bipolar disorder. Bipolar Disorders, 12(7), 727–740. CrossRefPubMed
32.
Xiao, L., Gao, Y. L., Zhang, L. L., Chen, P. Y., Sun, X. J., & Tang, S. Y. (2016). Validity and reliability of the Brief version of Quality of Life in Bipolar Disorder (Bref QoL.BD) among Chinese bipolar patients. Journal of Affective Disorders, 193, 66–72. CrossRefPubMed
33.
Polit, D. F., & Beck, C. T. (2006). The content validity index: Are you sure you know what’s being reported? critique and recommendations. Research in Nursing & Health, 29(5), 489–497. (Chinese journal). CrossRef
34.
Shi, J. C., Mo, X. K., & Sun, Z. Q. (2012). Content validity index in scale development. Journal of Central South University, 37(2), 152–155. (Chinese journal).
35.
Joreskog, K. G., & Sorbom, D. (1996). LISREL 8: User’s reference guide. Chicago: Scientific Software International.
36.
Kelloway, E. K. (1998). Using LISREL for structural equation modeling: A researcher’s guide. Thousand Oaks, CA: SAGE.
37.
Kline, R. B. (1998). Principals and practice of structural equation modeling. New York, NY: Guilford.
38.
39.
Bollen, K. A. (1989). Structural equation with latent variables. New York, NY: Wiley. CrossRef
40.
Bonnin, C. M., Sanchez-Moreno, J., Martinez-Aran, A., Sole, B., Reinares, M., Rosa, A. R., et al. (2012). Subthreshold symptoms in bipolar disorder: Impact on neurocognition, quality of life and disability. Journal of Affective Disorders, 136(3), 650–659. CrossRefPubMed
41.
Cochran, W. G. (1952). The χ 2 test of goodness of fit. The Annals of Mathematical Statistics, 23(3), 315–345. CrossRef
42.
Michalak, E. E., Yatham, L. N., & Lam, R. W. (2005). Quality of life in bipolar disorder: A review of the literature. Health and Quality of Life Outcomes, 3, 72. CrossRefPubMedPubMedCentral
43.
Morselli, P. L., Elgie, R., & Cesana, B. M. (2004). GAMIAN-Europe/BEAM survey II: Cross-national analysis of unemployment, family history, treatment satisfaction and impact of the bipolar disorder on life style. Bipolar Disorders, 6(6), 487–497. CrossRefPubMed
44.
Endicott, J., Rajagopalan, K., Minkwitz, M., & Macfadden, W. (2007). BOLDER Study Group. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: Improvements in quality of life. International Clinical Psychopharmacology, 22, 29–37. CrossRefPubMed
45.
Vornik, L. A., & Hirschfeld, R. M. (2005). Bipolar disorder: Quality of life and the impact of atypical antipsychotics. The American Journal of Managed Care, 11(Suppl. 9), 275–280.
46.
Perkins, D. O., Gu, H., Weiden, P. J., McEvoy, J. P., Hamer, R. M., & Lieberman, J. A. (2008). Predictors of treatment discontinuation and medication non-adherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: A randomized, double-blind, flexible-dose, multicenter study. Journal of Clinical Psychiatry, 69(1), 106–113. CrossRefPubMed
47.
Briggs, A., Wild, D., Lees, M., Reaney, M., Dursun, S., Parry, D., & Mukherjee, J. (2008). Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: Direct utility elicitation. Health and Quality of Life Outcomes, 6, 105. CrossRefPubMedPubMedCentral
48.
Hayhurst, H., Palmer, S., Abbott, R., Johnson, T., & Scott, J. (2006). Measuring health-related quality of life in bipolar disorder: Relationship of the EuroQol (EQ-5D) to condition-specific measures. Quality of Life Research, 15(7), 1271–1280. CrossRefPubMed
Metagegevens
Titel
Adaptation and validation of the “tolerability and quality of life” (TOOL) questionnaire in Chinese bipolar patients
Auteurs
Lin Xiao
Yulin Gao
Lili Zhang
Peiyun Chen
Xiaojia Sun
Siyuan Tang
Publicatiedatum
23-05-2016
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 11/2016
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-016-1319-1

Andere artikelen Uitgave 11/2016

Quality of Life Research 11/2016 Naar de uitgave

OriginalPaper

Patient-reported outcomes and surgical triage: A gap in patient-centered care?

Review

A review of empirical research related to the use of small quantitative samples in clinical outcome scale development

Review

The health-related quality of life of ankylosing spondylitis patients assessed by SF-36: a systematic review and meta-analysis

OriginalPaper

Measuring health-related quality of life in patients with conservatively managed stage 5 chronic kidney disease: limitations of the Medical Outcomes Study Short Form 36: SF-36

OriginalPaper

Phenylketonuria patients’ and their parents’ acceptance of the disease: multi-centre study

OriginalPaper

Health-related quality of life in patients with psoriasis: a systematic review of the European literature